Tuberculosis Treatment May Be Shortened
Main Category: TuberculosisArticle Date: 03 Sep 2009 - 3:00 PDT
| Patient / Public: | ![]() |
2.5 (2 votes) |
| Healthcare Prof: | ![]() |
According to Dutch researcher Hanneke Later-Nijland, it may be possible to shorten the duration of treatment for tuberculosis. Due to the long duration of treatment, not every patient sees it through. Partly because of this, tuberculosis is one of the most lethal diseases in developing countries.
The research conducted by Hanneke Later-Nijland is helping to shorten the duration of treatment for tuberculosis. Later-Nijland studied different groups of Indonesian tuberculosis patients. She believes it may be possible to shorten the duration of treatment by increasing the dose of the important drug rifampicin. After increasing the dose, the concentration of the drug in the blood plasma was higher than expected.
In addition, the tuberculosis patients in Later-Nijland's study did not experience more or different adverse effects at an increased dose than at a standard dose. Therefore increasing the dose of rifampicin might make it possible to reduce the length of treatment for tuberculosis without additional consequences. Research involving larger groups of patients will be needed to confirm this conclusion.
Tuberculosis and diabetes
Later-Nijland also conducted research into the reduced effectiveness of treatment in tuberculosis patients who also have type 2 diabetes. Her research revealed that the concentration of rifampicin in the blood plasma of patients with type 2 diabetes was lower than in patients with tuberculosis alone but who were administered the same dose. Whether tuberculosis patients with type 2 diabetes would benefit from a higher dose of rifampicin is a subject for further research.
Hanneke Later-Nijland started her research in October 2004 at Radboud University Nijmegen Medical Centre. She carried out her research within the Indonesian, Tanzanian and Dutch research network Poverty Related Infection Oriented Research, or PRIOR. PRIOR focused on research into poverty-related infectious diseases such as tuberculosis, HIV and malaria, and was funded by NWO.
Source: Netherlands Organization for Scientific Research
Visit our tuberculosis section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/162803.php>
APA
http://www.medicalnewstoday.com/releases/162803.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




